KUSH PARMAR - 02 Nov 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Director, 10%+ Owner
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol: TRDA
Transactions as of: 02 Nov 2021
Transactions value $: $5,000,000
Form type: 4
Filing time: 05 Nov 2021, 08:49:04 UTC
Previous filing: 01 Nov 2021
Next filing: 18 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Conversion of derivative security		+318,616	+96.2%		649,771	02 Nov 2021	See Footnote	F1, F2
transaction	TRDA	Common Stock	Conversion of derivative security		+2,371,739	+365%		3,021,510	02 Nov 2021	See Footnote	F1, F2
transaction	TRDA	Common Stock	Conversion of derivative security		+564,217			564,217	02 Nov 2021	See Footnote	F1, F3
transaction	TRDA	Common Stock	Conversion of derivative security		+254,512	+8.42%		3,276,022	02 Nov 2021	See Footnote	F1, F2
transaction	TRDA	Common Stock	Conversion of derivative security		+318,140	+56.4%		882,357	02 Nov 2021	See Footnote	F1, F3
transaction	TRDA	Common Stock	Purchase	$5,000,000	+250,000	+28.3%	$20.00	1,132,357	02 Nov 2021	See Footnote	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Series Seed Preferred Stock	Conversion of derivative security	$0	-318,616	-100%	$0.000000^*	0	02 Nov 2021	Common Stock	318,616		See Footnote	F1, F2
transaction	TRDA	Series A Preferred Stock	Conversion of derivative security	$0	-2,371,739	-100%	$0.000000^*	0	02 Nov 2021	Common Stock	2,371,739		See Footnote	F1, F2
transaction	TRDA	Series A Preferred Stock	Conversion of derivative security	$0	-564,217	-100%	$0.000000^*	0	02 Nov 2021	Common Stock	564,217		See Footnote	F1, F3
transaction	TRDA	Series B Preferred Stock	Conversion of derivative security	$0	-254,512	-100%	$0.000000^*	0	02 Nov 2021	Common Stock	254,512		See Footnote	F1, F2
transaction	TRDA	Series B Preferred Stock	Conversion of derivative security	$0	-318,140	-100%	$0.000000^*	0	02 Nov 2021	Common Stock	318,140		See Footnote	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F2	Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
F3	Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
F4	On November 2, 2021, Opportunities purchased 250,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.